Publications Venture Studios – Startup Formation & Initial Capitalization Considerations December 9, 2024
Experience Fenwick Represents BILL in $1.4B Offering of 0% Convertible Senior Notes Due 2030 December 6, 2024
Publications The Corporate Transparency Act: Reporting Deadline Stayed by Preliminary Injunction December 5, 2024
Experience Fenwick Represents Maze Therapeutics in $115M Oversubscribed Series D Financing December 3, 2024
Publications 2024 Proxy Season Results in Silicon Valley and Large Companies Nationwide December 2, 2024